Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: semaglutide

First Posted Date: 2014-08-08

Last Posted Date: 2018-03-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 87

Registration Number: NCT02212067

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Phase 1

Completed

Conditions: Hepatic Impaired
Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide

First Posted Date: 2014-08-07

Last Posted Date: 2017-12-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 44

Registration Number: NCT02210871

Locations: 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide
Drug: DPP-4 inhibitor

First Posted Date: 2014-08-04

Last Posted Date: 2019-01-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 601

Registration Number: NCT02207374

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan

Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors

Phase 1

Completed

Conditions: Obesity
Metabolism and Nutrition Disorder

Interventions: Drug: liraglutide

First Posted Date: 2014-08-04

Last Posted Date: 2016-12-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT02207348

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa

First Posted Date: 2014-08-04

Last Posted Date: 2021-11-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT02207218

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Phase 2

Completed

Conditions: Diabetes
Diabetes Mellitus Type 2

Interventions: Drug: Metformin
Drug: Liraglutide
Drug: Placebo
Drug: NNC0090-2746

First Posted Date: 2014-07-31

Last Posted Date: 2020-07-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 108

Registration Number: NCT02205528

Locations: 🇺🇸
Novo Nordisk Investigational Site, Manassas, Virginia, United States

Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: semaglutide

First Posted Date: 2014-06-24

Last Posted Date: 2014-10-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 78

Registration Number: NCT02172313

A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human Insulin

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin detemir
Drug: human soluble insulin

First Posted Date: 2014-06-12

Last Posted Date: 2014-06-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 13

Registration Number: NCT02162407

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Healthy
Diabetes

Interventions: Drug: placebo
Drug: semaglutide

First Posted Date: 2014-06-11

Last Posted Date: 2014-12-03

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 48

Registration Number: NCT02161588

Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus
Inflammation
Rheumatoid Arthritis
Healthy

Interventions: Drug: placebo
Drug: NNC 0151-0000-0000

First Posted Date: 2014-05-30

Last Posted Date: 2017-02-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 60

Registration Number: NCT02151409

Locations: 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy